TABLE 1.
Inhibitory effects of BCX 2798 and BCX 2855 in vitro
| Virus | Inhibitiona (mean concn [μM])
|
|||||
|---|---|---|---|---|---|---|
| HA activityb (mean IC50 ± SD)
|
NA activityc (mean IC50 ± SD)
|
Growth in LLC-MK2 cellsd (mean EC50 ± SD)
|
||||
| BCX 2798 | BCX 2855 | BCX 2798 | BCX 2855 | BCX 2798 | BCX 2855 | |
| hPIV-1 | 0.1 ± 0.0 | 6.0 ± 1.9 | 0.04 ± 0.0 | 1.2 ± 0.2 | 1.1 ± 0.3 | 11.5 ± 1.0 |
| hPIV-2 | 2.2 ± 0.6 | 2.7 ± 0.6 | 1.6 ± 0.4 | 1.9 ± 0.2 | 7.0 ± 0.0 | 1.8 ± 0.9 |
| hPIV-3 | 4.8 ± 0.1 | 2.0 ± 0.5 | 20.0 ± 1.7 | 4.3 ± 0.2 | 11.3 ± 1.1 | 2.4 ± 0.7 |
| rSV (hHN) | 0.1 ± 0.0 | 4.8 ± 0.1 | 0.02 ± 0.0 | 1.8 ± 0.3 | 0.7 ± 0.1 | 8.6 ± 1.3 |
| Total (range) | 0.1-4.8 | 2.0-6.0 | 0.02-20.0 | 1.2-4.3 | 0.7-11.3 | 1.8-11.5 |
a
Each mean concentration was calculated from values obtained from at least three independent experiments.
b
Determined in HI assays. IC50 values are the mean concentrations (except as noted) of the compound that caused 50% agglutination.
c
Determined in NI assays. IC50 values are the mean concentrations (except as noted) of the compound required to reduce the NA activity to 50% of that of untreated controls. MUN (final concentration, 150 μM) was the substrate.
d
Determined by endpoint dilution assays (TCID50). EC50 values are the mean concentrations (except as noted) of the compound required to inhibit virus replication in treated LLC-MK2 cells to 50% of that in untreated controls.